Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms.

ABSTRACT:

Background

Anti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed.

Objectives

The aim of this study was to summarize the characteristics and mechanisms of occurrence of five immunological and non-immunological adverse events caused by different anti-IL-23 agents.

Methods

The Cochrane Library, EMBASE, PubMed, and Web of Science databases were searched for eligible randomized clinical trials published from inception through May 1, 2020. Randomized clinical trials that reported at least one type of adverse event after treatment were included, regardless of sex, age, ethnicity, and diagnosis. Two investigators independently screened and extracted the charact

SUBMITTER: Ru Y 

PROVIDER: S-EPMC8226270 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature